2009
A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial
Oh W, Febbo P, Richie J, Fennessy F, Scibelli G, Hayes J, Choueiri T, Tempany C, Taplin M, Ross R. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal Of Clinical Oncology 2009, 27: 5060-5060. DOI: 10.1200/jco.2009.27.15_suppl.5060.Peer-Reviewed Original ResearchHigh-risk localized prostate cancerLocalized prostate cancerProstate cancerPSA declineGleason 7Neoadjuvant docetaxelRadical prostatectomyPhase II study of neoadjuvant chemotherapyClinical evidence of activityGrade 3 allergic reactionStudy of neoadjuvant chemotherapyPhase II multicenter trialBladder neck injuryMaximal tumor volumeMedian Gleason scoreTreated with docetaxelPhase II studyIntraoperative rectal injuryCT2 diseaseCT3 diseaseMedian PSARising PSAFebrile neutropeniaGleason 8Gleason score
2005
Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer
Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2005, 23: 9089-9096. PMID: 16301597, DOI: 10.1200/jco.2004.00.1438.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCetuximabDeoxycytidineDisease ProgressionDrug Administration ScheduleDrug EruptionsFemaleGemcitabineHumansInfusions, IntravenousLung NeoplasmsMaleMiddle AgedSurvival AnalysisTreatment OutcomeConceptsPhase I/IIa studyAdverse eventsIIa studyOverall survivalLung cancerToxicity profileResponse rateGrade 3 adverse eventsGrade 3 allergic reactionSmall cell lung cancerAcne-like rashMucositis/stomatitisCycles of therapyMedian overall survivalNausea/vomitingSafety/toxicity profileTumor response rateAcceptable toxicity profileFever/chillsCombination of cetuximabCell lung cancerAssessable patientsChemotherapy-naïveStable diseaseMedian survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply